Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
about
Targeted therapy for advanced renal cell carcinomaA pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer.Improved curve fits to summary survival data: application to economic evaluation of health technologies.Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting.Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway.URG4/URGCP enhances the angiogenic capacity of human hepatocellular carcinoma cells in vitro via activation of the NF-κB signaling pathway.Recent Advances in the Development of Antineoplastic Agents Derived from Natural ProductsImmunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patientsPercutaneous cryoablation of metastatic renal cell carcinoma for local tumor control: feasibility, outcomes, and estimated cost-effectiveness for palliation.Growth factor signaling in metastasis: current understanding and future opportunities.New insights into the management of renal cell cancer.Overview of parametric survival analysis for health-economic applications.Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma.Cost-effectiveness analysis of axitinib through a probabilistic decision model.Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis.Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma.Comment on 'costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib'.Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.Effects of cell-cell crosstalk on gene expression patterns in a cell model of renal cell carcinoma lung metastasis.Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma.Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
P2860
Q24242946-CEF17C53-BB00-404D-8FD0-61EE0787F05CQ33646171-CBF204AB-C218-4C01-8EB1-F5F6CDBA05C0Q34045267-BEE1CDEB-E338-472B-92B9-65B97D6F94BDQ34193184-9D18207B-419B-45BE-B25F-383545ABCA38Q34497997-E1381872-8ADE-487B-A335-9D0419E24A49Q34729901-01F5C57B-A75E-42E2-B99E-2C4446BD69A5Q35623604-77F31D8F-588F-4FDD-8711-09189660A5BBQ36273796-8801B7D6-E326-4FE8-B439-2787C778572EQ36421301-92D4584B-866D-489E-8994-BB7B3E083001Q37122053-9C219781-278D-4A40-B2E0-579C2BC92C4EQ37398545-1B1E4239-71AA-4328-8F59-70F03137C58FQ38019410-C436AF44-66B0-4773-B147-D8D1DCE68546Q38053049-972F5CEA-A017-46B7-9542-66AF7FEE635AQ38106867-A347D5F6-CA5B-49A0-8657-13104714CC21Q38367115-478DEAD0-A332-4F35-A129-B9E0246558A4Q38469815-C0C79DE5-4FC2-46BC-A42C-78DB0B547CF5Q39808042-7446DDE1-488C-4CB3-B30B-AE53D86C1209Q41898172-028AB49C-23C3-4FC7-B95A-C8E0462190F9Q42392542-C88394E2-98B9-4673-A0D4-36DFC2543E4DQ46233598-FD6B9052-34A1-4235-A069-9AF721C681A6Q46481747-86A200B5-831B-40AC-B869-2DD92BC9E9B4Q47246219-A0CC2779-863F-4D55-A5AF-7A7368787E55Q47975462-5F44063F-1BAB-4EF5-B025-55261CA0D62EQ58800689-2B858C9F-BF31-40D4-B157-17AC4B7C7BAC
P2860
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@ast
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@en
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@nl
type
label
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@ast
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@en
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@nl
prefLabel
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@ast
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@en
Bevacizumab, sorafenib tosylat ...... eview and economic evaluation.
@nl
P2093
P356
P1476
Bevacizumab, sorafenib tosylat ...... review and economic evaluation
@en
P2093
P304
1-184, iii-iv
P356
10.3310/HTA14020
P50
P577
2010-01-01T00:00:00Z